<< Back to Results
A phase III, multicenter, randomized, double-blind, placebo-controlled safety study of xolair (omalizumab) in patients with chronic idiopathic urticaria (CIU) who remain symptomatic despite treatment with H1 antihistamines, H2 blockers, and/or leukotriene receptor antagonists
- Principal Investigator(s)
- Robert Anolik, M.D.
Clinical Trial Categories
- Research Center of Allergy and Asthma Specialists at 877-877-8839